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Abstract
Background: Bladder cancer, cystitis and bladder polyp are the most common urinary system diseases all over the
world. Our former research results show that IL-17A and IL-17 F contribute to the pathogenesis of benign prostatic
hyperplasia (BPH) and prostate cancer (Pca) while IL-17E interacting with IL-17RB might have an anti-tumor effect.
Results: Using imunohistochemistry, we systemically compared immunoreactivity of ligands (IL-17A, E and F) and
receptors (IL-17RA, IL-17RB and IL-17RC) of IL-17 family, infiltration of inflammatory cells and changes of structural cells
(fibroblast cells, smooth muscle and vascular endothelial cells) in sections of bladder tissues from subjects with bladder
cancer, cystitis and bladder polyp. Compared with subjects with cystitis, immunoreactivity for IL-17A, IL-17 F and IL-17RC
was significantly elevated in the group of bladder cancer (p < 0.01), while immunoreactivity of IL-17E, IL-17RA and IL-17RB,
and the infiltrating neutrophils were decreased (p < 0.05). The numbers of infiltrating lymphocytes and phagocytes and
CD31+ blood vessels and immunoreactivity of CD90+ fibroblasts were also elevated in patients with bladder cancer
compared with those of cystitis. The patterns of IL-17 ligands and receptors, and inflammatory cells and structural cells
varied in cystitis, bladder polyp and bladder cancer. In bladder cancer, immunoreactivity of IL-17E and IL-17 F was
positively correlated with smooth muscles and lymphocytes, respectively. In addition, immunoreactivity of IL-17A and
IL-17E was positively correlated with their receptors IL-17RA and IL-17RB respectively.
Conclusions: The data suggest that changed patterns of expression of the IL-17 cytokine family ligands and receptors
might be associated with infiltration of inflammatory cells and structural cells (CD90+ fibroblasts and CD31+ blood
vessels), which might also contribute to occurrence and development in bladder cancer.
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Background
There are about 400,000 individuals with bladder cancer
in the world and 150,000 patients die from the disease
every year [1, 2]. In the United States bladder cancer is
the 5th most common type of cancer with 72,500 new
cases and 15, 200 deaths occurring in 2013 [3], while
cystitis and polyp are considered as high-risk for bladder
cancer [4]. It has been shown that multiple bladder
polyps and cystitis are easy to develop malignant disease
depending on the scope and duration of those relative
diseases [5]. Although many factors may be associated
with the pathogenesis and mechanisms of above
diseases, some cytokines, including tumor necrosis
factor-α (TNF-α), interleukin-17 (IL-17) cytokine family
and interferon (IFN) are considerably involved in the
occurrence and development of cystitis, bladder polyp
and bladder cancer [6, 7].
The IL-17 cytokine family includes six ligands (IL-17A to
IL-17 F) and five receptors (IL-17RA to IL-17RE). Because
of their unique and distinct biological functions, most
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studies are focused on IL-17A and IL-17E in tumors [8, 9].
In addition, IL-17 F has also been studied because of its high
molecular homology and similar biological functions with
IL-17A [10]. Previous studies have shown that both IL-17A
and IL-17E can bind to their receptors IL-17RA and IL-
17RB, while IL-17 F can bind to its own receptor IL-17RC
and/or IL-17RA to fulfill their biological function. It has
been indicated that IL-17A and IL-17 F are key pro-
inflammatory cytokines in the pathogenesis of inflammatory
and autoimmune diseases [11]. Compared with IL-17A/IL-
17 F, IL-17E plays an important role in the pathogenesis of
asthma and atopic diseases through binding to the hetero-
dimeric complex of IL-17RA/IL-17RB [12]. On the other
hand, some studies have also indicated the paradoxes of the
pro-tumor or anti-tumor activity of IL-17 family relative
ligands [11, 13]. Previous data have shown that macro-
phages secreting IL-17 family cytokines may play import-
ant roles in the pathogenesis of malignant tumors [14].
For example, it has been shown that IL-17A transcripts in
peripheral blood mononuclear cells [15] and serum con-
centrations of IL-17A [16] were significantly higher in per-
ipheral blood mononuclear cells in subjects with bladder
cancer than those of controls. In animal experiments, it
has been reported that IL-17A promoted bladder cancer
growth [17], while IL-17-producing γδ T cells possibly
play a key role in the Bacillus Calmette-Guéri (BCG)-in-
duced recruitment of neutrophils to the bladder, which is
essential for the antitumor activity against bladder cancer
[18]. However, the expression and location of other IL-17
family cytokines and their receptors, and their relation-
ships to bladder relative disease progression, inflammatory
cellular infiltration and structural changes are still largely
unclear in cystitis, bladder polyp and bladder cancer.
In this study we expanded our previous observations
in prostate cancer [19] and hypothesized that in bladder
tissues, both infiltrating inflammatory cells and struc-
tural cells can express IL-17 family cytokines and rele-
vant receptors, and that such expressions can affect not
only tissue remodelling but also angiogenesis, which are
associated with disease severity and tumorigenesis. We
compared expression and location of IL-17 cytokine
family IL-17A, IL-17E and IL-17 F and their receptors
IL-17RA, IL-17RB and IL-17RC in tissues derived from
subjects with cystitis, bladder polyp and bladder cancer
in parallel. We also analyzed the relationships between
expression of these IL-17 family cytokines and their re-
ceptors, infiltration of inflammatory cells and changes of
structural cells in these diseases.
Methods
Patients and specimens
The study was approved by the Hospital Ethics Committees
of Urinary System Diseases Prevention and Treatment
Research Centre of the Affiliated Hospital of Beihua Uni-
versity, Jilin City, Jilin Province, People’s Republic of China
(approval reference: 2012BH006), as formulated in the
World Medical Association Declaration of Helsinki. Writ-
ten and informed consents were provided by all subjects
participated, including 23 patients who were biopsied and
diagnosed as cystitis and 6 patients with hyperplastic blad-
der polyps from January 2012 to December 2014. Tumor
tissues were collected from 80 patients with transitional cell
carcinoma during surgical resection during the same time.
The above diseases were diagnosed as previously described
[20, 21]. The clinical characteristics of subjects involved in
this study are summarized in Table 1.
Immunohistochemistry
Immunohistochemistry was applied in paraffin sections
(4 μm thickness) to evaluate expression and location for
IL-17 family relative ligands (IL-17A, IL-17E and IL-
17 F) and their relative receptors (IL-17RA, IL-17RB and
IL-17RC), infiltration of inflammatory cells (T lympho-
cytes, macrophages, mast cells and neutrophils) and
relevant structural cells (CD90+ fibroblast cells, smooth
muscle and CD31+ vascular endothelial cells) as de-
scribed previously [19]. The sources of antibodies and
their optimal dilutions are indicated as Additional file 1:
Table S1. DAB kit (diaminobenzidine, ZhongShan
Golden Bridge Biological Company, Beijing, China) was
used to evaluate positive signals of immunestaining
while applying an irrelevant, matching isotype of IgG as
substitution of the primary antibody was used as nega-
tive control. All slides were blindly analysed by two ob-
servers using an Olympus microscope connected with a
computer running Image Pro Plus 6.0 software (Media
Table 1 Clinical characteristics of the subjects in this study
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Cybernetics, Maryland, USA). Global immunoreactivity
of IL-17 family relative cytokines as well as CD90+ cells
was quantified as the percentage staining of the total
stainable area of the sections defined with the haema-
toxylin counterstaining, while inflammatory cells (such
as lymphocytes, macrophages, neutrophils and mast
cells) and CD31+ blood vessels were quantified as the
numbers of immunoreactive cells per unit area of the
entire sections [18].
Statistical analysis
All the labeling area stained by the DAB in the immuno-
histochemistry procedure was measured, which based on
the principle of RGB color deconvolution using software
of NIH-Image J plugin. According to the sizes of slice
sides 6–20 fields, at 200 × original magnification, were
analyzed, and data were digitized and transferred to
NIH-Image J software. Data were analyzed with a statis-
tical package (Minitab for Windows, Minitab Release
9.2; Minitab, Inc, State College, PA). Nonparametric
Mann-Whitney test was used to analyze difference be-
tween groups. For all tests, p < 0.05 were considered as
significant. Data are presented in the Figures as the
median ± SD.
Results
Immunoreactivity and location of IL-17A and IL-17RA
Immunohistochemical staining analysis showed that glo-
bal IL-17A expression was significantly elevated in tissue
sections from bladder polyp and bladder cancer compared
with cystitis (Fig. 1a and b, p = 0.001 and p = 0.001, re-
spectively), while there was no significant difference in
global IL-17A immunoreactivity between bladder polyp
and bladder cancer (p = 0.170). IL-17A expression located
mainly in mononuclear cells, transitional epithelial cells,
malignant cells and vascular endothelial cells in bladder
cancer (Fig. 1a). In contrast to IL-17A, global IL-17RA
immunoreactivity was significantly elevated in cystitis
and polyp compared with those of bladder cancer
(Fig. 1c and d, p = 0.001 and p = 0.001, respectively),
while global IL-17RA immunoreactivity was signifi-
cantly higher in polyps than those of cystitis (p =
0.015). The location of IL-17RA immunoreactivity
was similar to IL-17A, which mainly located in transi-
tional epithelial cells, mononuclear cells in intersti-
tium and cancerous cells (Fig. 1c).
Immunoreactivity and location of IL-17E and IL-17RB
Global IL-17E expression was significantly elevated in
cystitis compared with those of bladder cancer (Fig. 2a
Fig. 1 Immunoreactivity of IL-17A and IL-17RA in cystitis, polyp and bladder cancer tissues. a Representative photomicrographs of IL-17A expression in
bladder sections from subjects with cystitis (n= 23), polyp (n= 6) and bladder cancer (n= 80) (original magnification × 10 and 20). b Quantitative analysis
of IL-17A expression area of bladder sections (% of whole sections). c Representative photomicrographs of IL-17RA expression in bladder sections from
cystitis, polyp and cancer. d Quantitative analysis of IL-17RA expression area of bladder sections (% of whole sections). Data are expressed as the mean ±
SEM. Arrows show examples of positively stained cells. The scale bar means 100 μm
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and b, p = 0.001), while there was no significant differ-
ence between cystitis and polyp (Fig. 2a and b, p =
0.093). Similar to IL-17A, IL-17E expression was pre-
dominantly observed in mononuclear cells, transitional
epithelial cells and vascular endothelial cells (Fig. 2a).
Global IL-17RB immunoreactivity was significantly
higher in the tissue sections from cystitis than that from
bladder cancer (Fig. 2c and d, p = 0.025). IL-17RB mainly
located in mononuclear cells, vascular endothelial cells,
smooth muscle cells and some cancerous cells (Fig. 2c).
Immunoreactivity and location of IL-17 F and IL-17RC
Global expression for IL-17 F was significantly greater in
the tissue sections from bladder cancer and polyp com-
pared with cystitis (Fig. 3a and b, p = 0.001and p = 0.008,
respectively), but there was no significant difference be-
tween bladder cancer and polyp (Fig. 3a and b, p =
0.294). IL-17 F mainly expressed in mononuclear cells,
transitional epithelial cells, vascular endothelial cells and
some malignant cells (Fig. 3a). Because IL-17 F can bind
not only to IL-17RA but also to IL-17RC to exert bio-
logical effects, we also evaluated global immunoreactivity
for IL-17RC in all the sections. Global expression for IL-
17RC was significantly increased in polyp and bladder
cancer compared with cystitis (Fig. 3c and d, p = 0.007,
p = 0.002), while there was no significant difference be-
tween polyp and bladder cancer (p = 0.127). Similar to
IL-17 F, IL-17RC immunoreactivity located principally in
mononuclear cells, transitional epithelial cells, vascular
endothelial cells and some malignant cells in bladder
cancer (Fig. 3c).
Infiltration of T lymphocytes and macrophages
Compared with cystitis, the numbers of CD3+ lymphocytes
increased in both polyps and bladder cancers but did not
achieve statistically significance (Fig. 4a and b, p = 0.273, p
= 0.384 respectively). These cells located predominately in
the stroma of polyp and bladder cancer. Like CD3+ lym-
phocytes, CD68+ macrophages also located mainly in
stroma of the bladder tissues. The median number of CD68
+ macrophages was significantly elevated in bladder cancers
compared with cystitis and polyps (Fig. 4c and d, p = 0.001,
p = 0.006 respectively). However, there was no obvious dif-
ference between cystitis and polyp (p = 0.3774).
Infiltration of neutrophils and mast cells
In order to explore other inflammatory cells infiltration,
we further detected elastase+ neutrophils and tryptase+
mast cells in the sections from bladder tissues. Both
mast cells and neutrophils mainly located in stroma. The
Fig. 2 Immunoreactivity of IL-17E and IL-17RB in cystitis, polyp and bladder cancer tissues. a Representative photomicrographs of IL-17E expression in bladder
sections from subjects with cystitis (n= 23), polyp (n= 6) and bladder cancer (n= 80) (original magnification × 10 and 20). b Quantitative analysis of IL-17E
expression area of bladder sections (% of whole sections). c Representative photomicrographs of IL-17RB expression in bladder sections from cystitis, polyp
and cancer. d Quantitative analysis of IL-17RB expression area of bladder sections (% of whole sections). Data are expressed as the mean± SEM. Arrows show
examples of positively stained cells. The scale bar means 100 μm
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Fig. 3 Immunoreactivity of IL-17 F and IL-17RC in cystitis, polyp and bladder cancer tissues a Representative photomicrographs of IL-17 F expression
in bladder sections from subjects with cystitis (n = 23), polyp (n = 6) and bladder cancer (n = 80) (original magnification × 10 and 20). b Quantitative
analysis of IL-17 F expression area of bladder sections (% of whole sections). c Representative photomicrographs of IL-17RC expression in bladder
sections from cystitis, polyp and cancer. d Quantitative analysis of IL-17RC expression area of bladder sections (% of whole sections). Data are expressed
as the mean ± SEM. Arrows show examples of positively stained cells. The scale bar means 100 μm
Fig. 4 Infiltration T cells and macrophages in cystitis, polyp and bladder cancer tissues. a and c Representative photomicrographs of CD3+ T cells and
CD68+ macrophages in bladder sections from subjects with cystitis (n = 23), polyp (n = 6) and bladder cancer (n = 80) (original magnification × 10 and
20). b and d Quantitative analysis of numbers of CD3+ T cells and CD68+ macrophages per unit area of bladder sections. Data are expressed as the
mean ± SEM. Arrows show examples of positively stained cells. The scale bar means 100 μm
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median numbers of mast cells were slightly higher in cystitis
and bladder cancer, but no statistical difference compared
with polyps (Fig. 5a and b, p= 0.227, p = 0.123, respectively),
and again there was no significant difference was achieved
between cystitis and bladder cancer (p= 0.440) (Fig. 5a and
b). The median number of neutrophils in cystitis compared
was significantly elevated with polyp and bladder cancer
(Fig. 5c and d, p= 0.023, p= 0.001, respectively), while there
was no obvious difference between polyp and bladder cancer
(p= 0.884) (Fig. 5c and d).
Changing of structural cells
We also evaluated the changing of some types of structural
cells in tissues such as α-actin+ smooth muscle, CD90+
fibroblast cells and CD31+ vascular endothelial cells. The
median expression of smooth muscle cells was slightly de-
creased in bladder cancer, but there were no statistical dif-
ferences among three groups (Fig. 6a and b). The median
immunoreactivity of CD90+ cells per unit area of the tissue
was dramatically elevated in bladder cancer compared with
cystitis and polyp (Fig. 6c and d, p = 0.006, p = 0.038, re-
spectively), but no statistical difference was observed be-
tween cystitis and polyps (Fig. 6c and d, p = 0.439). The
median number of CD31+ blood vessels was significantly el-
evated in the tissue sections from bladder cancer compared
with those of cystitis (Fig. 7a and b, p = 0.001). Although
the median number of CD31+ blood vessels also increased
in polyps, this did not achieve statistical significance com-
pared with cystitis (Fig. 7a and b, p = 0.064).
The relationship of expression for IL-17 cytokine family
ligands and their receptors, infiltration of inflammatory
cells and changes in structural cells in bladder cancer
In order to explore the correlations between IL-17 family
cytokines, and inflammatory cells as well as structural
cells, we further analyzed correlations of global expression
for IL-17 family ligands and their receptors and relevant
phenotypes of cells in bladder cancer. Of great interest,
global immunoreactivity for IL-17RA significantly corre-
lated with its ligand IL-17A (Fig. 8a, r = 0.298, p = 0.005),
while IL-17E significantly correlated with its receptor IL-
17RB (Fig. 8b, r = 0.409, p = 0.0001). In addition, global
immunoreactivity for α-actin+smooth muscle was signifi-
cantly correlated with IL-17E (Fig. 8c, r = 0.301, p = 0.001),
while the numbers of CD31+ blood vessels significantly
correlated with IL-17 F in bladder cancer tissues (Fig. 8d,
r = 0.301, p = 0.013).
Discussion
Although a numbers of previous studies seem to prove
that IL-17 family cytokines have the capability to pro-
mote occurrence and development of cystitis, polyp and
bladder cancer [22–25], there is a lack of systematically
comparison study of IL-17 family ligands and their
Fig. 5 Infiltration of mast cellsand neutrophils in cystitis, polyp and bladder cancer tissues. a and c Representative photomicrographs of tryptase+
mast cells and elastase+ neutrophils in bladder sections from subjects with cystitis (n = 23), polyp (n = 6) and bladder cancer (n = 80) (original
magnification × 10 and 20). b and d Quantitative analysis of numbers of tryptase+ mast cells and elastase+ neutrophils per unit area of bladder
sections. Data are expressed as the mean ± SEM. Arrows show examples of positively stained cells. The scale bar means 100 μm
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corresponding receptors in these urinary system dis-
eases. Here we analyzed the IL-17 family cytokines IL-
17A, E and F and their receptors IL-17RA, RB and RC
in bladder tissues from patients with cystitis, polyp and
bladder cancer. We also simultaneously examined in-
flammatory cellular infiltration, structural changes and
angiogenesis in these urinary disorders.
Accumulation of infiltrating inflammatory cells is a
typical feature of cystitis, possibly in bladder cancer as
well. However, proinflammatory responses are double-
edged sword with protective and tumorgenesis roles. On
the one hand, such accumulated phagocytes might cause
further inflammation in bladder tissues, which possibly
exerts an anti-tumor activity, through generating more
inflammatory mediators, including IL-17 family cyto-
kines. On the other hand, these mediators and cytokines,
in turn, might promote and enhance the abnormal cellu-
lar proliferation associated with polyp and bladder can-
cer, through generating various mediators, including
inflammatory cytokines such as interleukin-6 (IL-6) and
cellular growth factor (TGF-β) [23, 25, 26]. Our data
showed that expression of IL-17 cytokine family ligands
Fig. 6 Expression for smooth muscle and CD90+ fibroblasts in cystitis, polyp and bladder cancer tissues. a and c Representative photomicrographs of
smooth muscle and CD90+ fibroblasts with cystitis (n = 23), polyp (n = 6) and bladder cancer (n = 80) (original magnification × 10 and 20). b and d
Quantitative analysis of smooth muscle and CD90+ fibroblast immunoreactive area of bladder sections (% of whole sections). Data are expressed as
the mean ± SEM. Arrows show examples of positively stained cells. The scale bar means 100 μm
Fig. 7 CD31+ blood vessels in cystitis, polyp and bladder cancer tissues. a Representative photomicrographs of CD31+ blood vessels with cystitis (n= 23),
polyp (n= 6) and bladder cancer (n= 80) (original magnification × 10 and 20). b Quantitative analysis of numbers of CD31+ blood vessels per unit area of
bladder sections. Data are expressed as the mean ± SEM. Arrows show examples of positively stained endothelial cells. The scale bar means 100 μm
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and their relevant receptors was accompanied with mark-
edly distinct profiles of infiltration of inflammatory cells in
various conditions of urinary disorders. For example, ele-
vated expressions of IL-17A, IL-17 F and IL-17RC and in-
creased numbers of macrophages were observed in
bladder cancer. One possible explanation may be that IL-
17A and IL-17 F and IL-17RC can be expressed by these
macrophages in bladder cancer. However, expression of
IL-17A, IL-17RA and IL-17RC also increased in polyps
but with the downgrade of numbers of macrophages. This
suggests that macrophages might not be major source of
these members of IL-17 family in polyps.
Additionally, other changed abnormal structural cells
such as endothelial cells and fibroblasts were also ob-
served in bladder cancer, which might contribute to the
increases of immunoreactivity for IL-17A, IL-17 F and
IL-17RC. It has been known that IL-17A and IL-17 F
can bind to both IL-17RA and IL-17RC. For example,
IL-17 F exerts effects on angiogenesis, while the elevated
vessels in turn contribute to elevation of IL-17A or IL-
17 F production in bladder cancer [27], which formats a
positive feedback to promote malignant proliferation. In
the present study, expression of IL-17A and IL-17 F in-
creased but IL-17RA decreased in bladder cancer, sug-
gesting that IL-17A and IL-17 F are possibly expressed
by different profiles of cellular populations and mainly
through binding IL-17RC to exert biological effects.
Although we observed that some immunoreactivity for
IL-17A and IL-17 F located in malignant cells, however,
until far, there is lack of systemic study whether malig-
nant cells in bladder cancer express IL-17A or IL-17 F.
Clearly further experiments remain to be performed in
this aspect.
IL-17E, through binding to its own receptor IL-17RB
or IL-17RA, shows different properties from IL-17A and
IL-17 F in tumor fields. Our data here showed that IL-
17E and IL-17RB expression was elevated in cystitis but
reduced in bladder cancer, possibly indicating that IL-
17E might also be involved in the pathogenesis of benign
urinary diseases. On one hand, IL-17E might participate
in the pathogenesis of inflammation through acting on
its receptor IL-17RB expressed on inflammatory cells
and structural cells, which results in inflammation and
alternation of structural cells. On the other hand, it is in-
teresting that reduced expression of IL-17E and IL-17RB
in bladder cancer. Such reduction in bladder cancer is
possibly because the damaged or abnormal structural
cells and malignant cells express less IL-17E and its re-
ceptor IL-17RB. This might affect anti-tumor effect of
IL-17E in bladder cancer. Again, however, the details
and underlying mechanisms of IL-17E in the pathogen-
esis of bladder cancer remain to be explored.
Our results also show that there were more vascular
endothelial cells in bladder cancer compared with cystitis.
Fig. 8 The relationship between IL-17 family related ligands, receptors, inflammatory cells and structural cells in bladder cancer. a Positive correlation
between IL-17A and IL-17RA. b Positive correlation between IL-17E and IL-17RB. c Positive correlation between smooth muscle and IL-17E. d Positive
correlation between IL-17 F expression and infiltration of lymphocytes
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It is well known that in bladder cancer, over-proliferation
of cancer cells need more blood supplying, while these
malignant cells and increased angiogenesis might affect
other cell proliferation. On the other hand, vascular endo-
thelial cells can express IL-17 family cytokine which might
attract more inflammatory cells into malignant tissues and
promote occurrence and development of bladder cancer.
Apart of blood vessels, increased immunoreactivity for
CD90+ fibroblasts was observed in bladder cancer, sug-
gesting that these fibroblasts might also contribute to ex-
pression of IL-17 family ligands and receptors and
possibly to pathogenesis of bladder cancer, through en-
hancing tumor growth [28, 29].
Since inflammatory microenvironment is a feature in
urinary tract diseases while the relative members of IL-
17 cytokine family closely link with inflammation, we
also examined the status of common inflammatory cell
types in the present study. The increased numbers of
CD3+ T lymphocytes and CD68+ macrophage in bladder
cancer suggest that these cells might participate in the
process of bladder cancer. Macrophage is an important
component of the inflammatory and tumor microenvir-
onment and plays a key role in the progression of
tumors. It has been shown that macrophage has dual
function according to different tumor types [30]. Its
function is, however, extremely complex and has not
been elucidated till now. Neutrophil infiltration is a
typical characteristic of acute inflammation. We also ob-
served that there were more neutrophils in cystitis tissue
than polyp and cancer, accompanied with increased IL-
17RA, IL-17E and IL-17RB expression. Although
neutrophils might not express IL-17E, these cells do ex-
press IL-17RA/or IL-17RB.
In addition, close correlations of expression of IL-17A-
IL-17RA and IL-17E-IL-17RB suggest that different signal-
ing of IL-17A-IL-17RA and IL-17E-IL-17RB might play an
important role in bladder cancer. It is known that smooth
muscle can express IL-17E. Thus, it is reasonably to pre-
sume that these cells might be a major cellular source of
IL-17E, which may partly explain that the decreased IL-17E
expression is a part of result due to the reduction of smooth
muscle in bladder cancer. At the mean time, slight but sig-
nificant correlation between immunoreactivity of IL-17 F
and the numbers of CD3+ T lymphocytes was observed in
bladder cancer, suggesting that CD3+ T lymphocytes might
also be a major cellular source expressing IL-17 F. Whether
these IL-17 F+ CD3+ T cells are a subgroup of Th17 cells
remains to be investigated.
Obviously our study has some limitations. Firstly, it is
still unknown for certain whether the specific index
assessed by immunohistochemistry has been accurately
identified. Clearly other experiments need to be done to
confirm the roles of IL-17A and IL-17E signals in blad-
der cancer occurrence and development. Secondly, there
were no entirely normal bladder specimens as controls,
which might affect the comparison among the groups.
Conclusion
Taking together our data indicate that changes of inflam-
matory and structural cells might be associated with the
variable expression of IL-17 family cytokines, while in-
creased blood endothelial cells and fibroblasts might be as-
sociated with bladder cancer occurrence and development.
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